- Home
- SIGA vs KIO Comparison
SIGA vs KIO Comparison
Compare SIGA & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- KIO
- Stock Information
- Founded
- SIGA 1995
- KIO 2011
- Country
- SIGA United States
- KIO United States
- Employees
- SIGA N/A
- KIO 2400
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- KIO Investment Managers
- Sector
- SIGA Health Care
- KIO Finance
- Exchange
- SIGA Nasdaq
- KIO Nasdaq
- Market Cap
- SIGA 515.1M
- KIO 522.7M
- IPO Year
- SIGA 1997
- KIO N/A
- Fundamental
- Price
- SIGA $9.13
- KIO $12.46
- Analyst Decision
- SIGA
- KIO
- Analyst Count
- SIGA 0
- KIO 0
- Target Price
- SIGA N/A
- KIO N/A
- AVG Volume (30 Days)
- SIGA 640.7K
- KIO 136.5K
- Earning Date
- SIGA 08-05-2025
- KIO 01-01-0001
- Dividend Yield
- SIGA 6.57%
- KIO 10.82%
- EPS Growth
- SIGA N/A
- KIO N/A
- EPS
- SIGA 1.14
- KIO N/A
- Revenue
- SIGA $179,639,422.00
- KIO N/A
- Revenue This Year
- SIGA N/A
- KIO N/A
- Revenue Next Year
- SIGA $95.31
- KIO N/A
- P/E Ratio
- SIGA $8.01
- KIO N/A
- Revenue Growth
- SIGA 3.86
- KIO N/A
- 52 Week Low
- SIGA $4.95
- KIO $10.52
- 52 Week High
- SIGA $9.80
- KIO $13.59
- Technical
- Relative Strength Index (RSI)
- SIGA 67.83
- KIO 42.25
- Support Level
- SIGA $8.39
- KIO $12.26
- Resistance Level
- SIGA $9.14
- KIO $12.70
- Average True Range (ATR)
- SIGA 0.50
- KIO 0.10
- MACD
- SIGA 0.04
- KIO -0.04
- Stochastic Oscillator
- SIGA 84.19
- KIO 34.21
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.